Introducing “Lecanemab Frequently Asked Questions“: On July 6, 2023, the FDA granted approval to lecanemab (Leqembi), a medication developed by Eisai and Biogen, for the treatment of early-stage Alzheimer’s disease. Lecanemab, administered through intravenous infusion every two weeks, is a monoclonal antibody designed to bind and remove amyloid plaques in the brain, which are associated with Alzheimer’s disease. While it does not provide a cure, lecanemab has demonstrated the potential to slow the progression of the disease, with a 27% reduction in cognitive decline observed in clinical trials. This FAQ document addresses various questions about lecanemab, including its administration, safety, candidacy requirements, availability, and associated costs. Please note that additional steps are required before the medication becomes available, and Medicare coverage is subject to certain conditions and costs.
Click Here to read the full FAQ document.
